Optimus Pharma granted permission for Restricted Use under Emergency Situation from the DCGI for its COVID-19 pill MOLNUPIRAVIR

Business

Hyderabad (Telangana) [India], December 28: Hyderabad, Optimus Pharma announced launching of their front line COVID-19 medication Molnupiravir in the Indian market, as they have received permission the restricted emergency use for Covid-19 drug.  Optimus Pharma successfully completed the Phase 3 Clinical Trial on 1218 subjects across 29 geographical study sites all over India. “We want to cover maximum demographic diversity into our trial in order to obtain data across the different geographical regions of the country and conclusive evidence that Molnupiravir is able to bring about viral load reduction over 5 days of treatment duration,” said Chairman and Managing Director of Optimus Pharma, Dr D Srinivasa Reddy. Optimus Pharma has developed the API in the house at its R&D centre in Hyderabad. Optimus Pharma has revealed highly promising results of the drug in its ability to reduce viral load and bring out significant symptomatic improvement in patients’ health.

It is to be noted that in the Clinical Trial, Molnupiravir was administered to the subjects along with Standard of Care (SoC) medication as per the approved protocol by CDSCO. The trial was successful in establishing a clinical significant results of ‘Molnupiravir + SoC’ over ‘SoC’ arm.

  • Rate of hospitalization was less in Molnupiravir+SoC when compared to SoC group.
  • Greater clinical improvement observed in Molnupiravir + SoC arm compared to SOC alone by Day 5 and Day 10.
  • Proportion of subjects with RT-PCR negativity at Day 5 and Day 10 was statistically significant in Molnupiravir + SoC arm.
  • Higher viral load reduction was observed in Molnupiravir+ SoC arm
  • No serious safety concerns observed with Molnupiravir in overall study duration, no mortality was observed in the trial across both the arms

 Molnupiravir is administered as an 800 mg dose by orally consuming four capsules of 200mg twice a day. Upon oral administration, Molnupiravir, being a prodrug, is metabolized into its active form and converted into its triphosphate (TP) form. The TP form of Molnupiravir is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription, thereby significantly reducing viral replication.

Optimus Pharma is ready with a commercial quantity of the drug to cater to the unmet medical need of the nation. It is with heartfelt gratitude that we thank the Subject Expert Committee of the CDSCO and the DCGI for their valuable recommendations and guidance for the Clinical Trial, thereby making this project a huge success, said Dr D. Srinivas Reddy (MD Optimus) in his statement to the press. Optimus Pharma is committed to consistently integrating quality, affordability and reliability into their products and ensuring timely access to life-saving medication to whomsoever is in need.

12 thoughts on “Optimus Pharma granted permission for Restricted Use under Emergency Situation from the DCGI for its COVID-19 pill MOLNUPIRAVIR

  1. Pretty portion of content. I just stumbled upon your website and in accession capital to assert that I get actually enjoyed account your weblog posts. Any way I will be subscribing for your augment or even I success you get right of entry to consistently rapidly.

  2. I?¦ve been exploring for a little bit for any high-quality articles or blog posts in this sort of house . Exploring in Yahoo I ultimately stumbled upon this site. Reading this information So i?¦m happy to express that I have an incredibly just right uncanny feeling I discovered just what I needed. I such a lot certainly will make certain to don?¦t fail to remember this web site and provides it a look regularly.

  3. I was wondering if you ever thought of changing the layout of your site? Its very well written; I love what youve got to say. But maybe you could a little more in the way of content so people could connect with it better. Youve got an awful lot of text for only having one or 2 images. Maybe you could space it out better?

  4. Hi would you mind stating which blog platform you’re using? I’m planning to start my own blog soon but I’m having a difficult time choosing between BlogEngine/Wordpress/B2evolution and Drupal. The reason I ask is because your design and style seems different then most blogs and I’m looking for something unique. P.S Sorry for getting off-topic but I had to ask!

Leave a Reply

Your email address will not be published.